Colorectal Cancer
Stay up to date on practice-changing data in community practice.
Leronlimab Gets FDA Nod for Phase 2 Microsatellite-Stable CRC Trial
A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable metastatic colorectal cancer.
Read More
Behind the FDA Approval of Fruquintinib for Previously Treated mCRC
In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.
Listen
BREAKWATER Trial Highlights ORR Boost in BRAF V600E mCRC
For Colorectal Cancer Awareness Month, Scott Kopetz, MD, PhD, FACP, discussed the BREAKWATER trial in metastatic BRAF V600E-mutated colorectal cancer.
Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers
In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer
Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite stable metastatic colorectal cancer without liver metastases.
Bevacizumab Benefits in CRC Persist for Two Years After Initiation
Bevacizumab's survival benefits in CRC patients persist for about 2 years after starting treatment.
